About Interferon-induced protein 44-like
Interferon-induced protein 44-like (IFI44L) is a protein
from Homo sapiens identified by UniProt accession
Q53G44, 452 residues long.
MolForge cross-references it against 0 known binders and
184 disease associations.
Target properties
| Protein name | Interferon-induced protein 44-like |
| UniProt accession | Q53G44 |
| Gene | IFI44L |
| Organism | Homo sapiens |
| Length | 452 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (184)
Diseases linked to this target (Open Targets).
- response to vaccine · score 0.37
- MMR-related febrile seizures · score 0.37
- Febrile seizure (within the age range of 3 months to 6 years) · score 0.30
- bipolar disorder · score 0.24
- CINCA syndrome · score 0.18
- schizophrenia · score 0.18
- sleep duration · score 0.17
- Systemic lupus erythematosus · score 0.09
- vital capacity · score 0.08
- leukocyte count · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q53G44-F1 | alphafold | PREDICTED | 86.07 | — |
Amino-acid sequence (452 residues)
MEVTTRLTWN DENHLRKLLG NVSLSLLYKS SVHGGSIEDM VERCSRQGCT ITMAYIDYNM IVAFMLGNYI NLHESSTEPN DSLWFSLQKK NDTTEIETLL LNTAPKIIDE QLVCRLSKTD IFIICRDNKI YLDKMITRNL KLRFYGHRQY LECEVFRVEG IKDNLDDIKR IIKAREHRNR LLADIRDYRP YADLVSEIRI LLVGPVGSGK SSFFNSVKSI FHGHVTGQAV VGSDITSITE RYRIYSVKDG KNGKSLPFML CDTMGLDGAE GAGLCMDDIP HILKGCMPDR YQFNSRKPIT PEHSTFITSP SLKDRIHCVA YVLDINSIDN LYSKMLAKVK QVHKEVLNCG IAYVALLTKV DDCSEVLQDN FLNMSRSMTS QSRVMNVHKM LGIPISNILM VGNYASDLEL DPMKDILILS ALRQMLRAAD DFLEDLPLEE TGAIERALQP CI
Explore Interferon-induced protein 44-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets